Ratings SyntheticMR AB

Equities

SYNT

SE0015987946

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
27.7 ^SEK	+1.09%		-.--%	+4.14%

Apr. 17	SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities	CI
Mar. 27	SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

With an expected P/E ratio at 50.52 and 29.24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SYNTHETICMR AB	+4.14%	106M		D
VEEVA SYSTEMS INC.	+4.71%	32.58B		C
PRO MEDICUS LIMITED	+16.80%	7.65B		C-
SECTRA AB	+23.49%	3.92B		B-
EVOLENT HEALTH, INC.	-15.80%	3.19B		C-
OMNICELL, INC.	-27.19%	1.26B		B
LUNIT INC.	-33.58%	1.14B		-
B-SOFT CO.,LTD.	-33.74%	926M		-
SIMULATIONS PLUS, INC.	+1.56%	908M		C
VERADIGM INC.	-23.93%	859M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders